Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Goodwill & Intangibles: 2015-2025

Historic Goodwill & Intangibles for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to $55.4 million.

  • Aytu Biopharma's Goodwill & Intangibles fell 22.48% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year decrease of 22.48%. This contributed to the annual value of $55.4 million for FY2025, which is 22.48% down from last year.
  • As of Q3 2025, Aytu Biopharma's Goodwill & Intangibles stood at $55.4 million, which was down 0.00% from $55.4 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Goodwill & Intangibles peaked at $180.4 million during Q1 2021, and registered a low of $55.4 million during Q2 2025.
  • Moreover, its 3-year median value for Goodwill & Intangibles was $71.5 million (2025), whereas its average is $72.6 million.
  • Per our database at Business Quant, Aytu Biopharma's Goodwill & Intangibles skyrocketed by 107.97% in 2021 and then plummeted by 42.99% in 2022.
  • Over the past 5 years, Aytu Biopharma's Goodwill & Intangibles (Quarterly) stood at $140.6 million in 2021, then plummeted by 36.29% to $89.6 million in 2022, then fell by 13.04% to $77.9 million in 2023, then fell by 8.23% to $71.5 million in 2024, then declined by 22.48% to $55.4 million in 2025.
  • Its last three reported values are $55.4 million in Q3 2025, $55.4 million for Q2 2025, and $71.5 million during Q1 2025.